The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer

The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer

BackgroundProtein tyrosine kinase (PTK) signaling pathway has been confirmed to be involved in the proliferation, differentiation and migration of tumor cells. Anlotinib, as a multi-target tyrosine kinase inhibitor, which can inhibit the expression of vascular endothelial growth factor receptor (VEG...

Full description

Bibliographic Details
Main Authors: Wubin Zheng, Guoqiang Sun, Zhitao Li, Fan Wu, Guangshun Sun, Hongyong Cao, Jin Zhou, Yong Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Surgery
Subjects:
anlotinib
gastric cancer
PD1
immunotherapy
VEGFR - vascular endothelial growth factor receptor
Online Access:https://www.frontiersin.org/articles/10.3389/fsurg.2022.895982/full

Internet

https://www.frontiersin.org/articles/10.3389/fsurg.2022.895982/full

Similar Items